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Introduction. Brugada syndrome accounts for about 4% of sudden cardiac deaths (SCD). It is characterized by an ST-segment
elevation in the right precordial electrocardiogram (EKG) leads. Case Presentation. We describe a 39-year-old healthy Caucasian
man who was admitted to the intensive care unit after being cardioverted from ventricular ﬁbrillation (VF) arrest. His past history
was signiﬁcant for an episode of syncope one month prior to this presentation for which he was admitted to an outlying hospital.
EKG during that admission showed ST elevations in V1 and V2 leads, a pattern similar to Type 1 Brugada. A diagnosis of Brugada
syndrome was missed and the patient had a cardiac arrest a month later. We discuss a short review of Brugada syndrome and
emphasize the need to look for it in patients presenting with SCD and malignant arrhythmias. Conclusion. Physicians should
always consider Brugada syndrome in the diﬀerential diagnosis of ST-segment elevation in anterior precordial leads of EKG and
associated VT/VF. Although more than 17 years have passed since the ﬁrst case was reported, increased awareness of this syndrome
is needed to identify patients with EKG changes and treat them accordingly to prevent incidence of (SCD) and its deleterious
complications.
1.Introduction
Brugada syndrome is a clinical entity ﬁrst described in 1992
[1]. It is an autosomal dominant genetically predisposed
disorder, characterized by an ST-segment elevation in the
right precordial EKG leads and a high incidence of sudden
cardiac death (SCD) in patients with structurally normal
hearts. Almost 4% of patients presenting with SCD have
Brugada syndrome, and therefore it should be looked for
in patients with SCD. It is more common in males than
females and typically ﬁrst presents in the third decade of life,
although it has been reported in children and the elderly too
[2]. We present a case whose diagnosis is missed in the early
presentation and developed SCD and its sequelae.
2.CaseDescription
A 39-year-old Caucasian man, with a past medical history
of hypothyroidism, on synthroid, and no prior history of
coronary artery disease, was in his usual state of health
until he suddenly developed abnormal respiration and loud
snoring while sleeping. His wife, who was awakened by
the loud snort, found him unresponsive. Immediately she
called emergency medical services (EMS) and initiated
cardiopulmonaryresuscitation.EMSarrived10minuteslater
and found the patient to be in ventricular ﬁbrillation. He
was successfully converted to sinus rhythm by multiple
external deﬁbrillations. He was intubated in the ﬁeld and
was then brought to the intensive care unit and initiated
on a hypothermia protocol. After reviewing the records
from his previous hospitalization, a signiﬁcant episode of
syncope occurring one month prior to this presentation
was discovered. Electrocardiogram (EKG) at that admission
showed sinus rhythm with incomplete right bundle branch
block and persistent ST elevation in V1 and V2 leads, a
pattern similar to type 1 Brugada syndrome (Figure 1).
During this admission he was ruled out for myocardial








Figure 1: Electrocardiogram showing descendent ST-segment elevation with negative T waves (white arrow heads) in the right precordial
leads V1 and V2.
with further workup. His initial transthoracic echocardio-
graphy (TTE) was signiﬁcant for ejection fraction (EF) of
25% with global hypokinesis. Subsequent transesophageal
echocardiography (TEE) showed normal left ventricular
functionwithejectionfractionof65%.Acardiaccatheteriza-
tion revealed no signiﬁcant coronary artery disease. During
the entire admission the patient was in sinus rhythm and
developed visual changes secondary to anoxic brain injury.
An implantable cardioverter-deﬁbrillator (ICD) placement
was done as per current recommendations and the patient
was subsequently discharged.
3. Discussion
Brugada syndrome has three types according to the EKG
patterns.Type1hasa“coved-”typeSTelevationwithatleast
2mm J-point elevation, a gradually descending ST-segment
andanegativeTwaveinmorethanonerightprecordialleads
(V1–V3). Type 2 has a “saddleback” pattern with at least
2mm J-point elevation, and at least 1mm ST elevation, with
a positive orbiphasic T wave. Type 2 pattern canoccasionally
be seen in healthy subjects. Type 3 has a saddle back or coved
pattern with less than 2mm J-point elevation, and less than
1mm ST elevation, with a positive T wave. Type 3 pattern
is not uncommon in healthy subjects. The type 2 and type
3 Brugada patterns are not speciﬁc enough to be considered
diagnostic [2].
The pathophysiology of the Brugada Syndrome is still in
debate between depolarization and repolarization hypothe-
sis. According to Wilde et al. there is compelling evidence
favoring repolarization hypothesis [3]. Dominant loss-of-
function mutations in cardiac myocyte sodium channel
encoding gene, named SCN5A [4], have been well doc-
umented in several cases. Other mutations in Glycerol-
3-phosphate dehydrogenase-like peptide, L-type calcium
channel (CACNA1c and its β subunit CACNB2b), and
potassium outward current channel also have an association
with Brugada syndrome [5]. New mutations are being
added to the current literature on regular basis. Genetic
testing for Brugada syndrome may conﬁrm a diagnosis in
patients suspected of having Brugada syndrome, as well as
diﬀerentiate between relatives who are at risk for the disease
and those who are not.
The Brugada pattern is a dynamic EKG ﬁnding, and it
may not always appear on 12-lead EKG. A drug challenge
test is used to establish the diagnosis; however, this test is
not required if the type-1 Brugada pattern exists on the 12-
lead EKG. Ajmaline, ﬂecainide, pilsicainide, procainamide,
disopyramide, and propafenone are the drugs utilized to
unmask Brugada syndrome [2, 6]. It is deﬁnitively diagnosed
when a type 1 ST-segment elevation is observed in >1r i g h t
precordial lead (V1 to V3) in the presence or absence of a
sodiumchannel-blockingagent,andinconjunctionwithone
of the following: documented ventricular ﬁbrillation (VF),
polymorphic ventricular tachycardia (VT), a family history
of sudden cardiac death at <45 years old, coved-type EKGs
in family members, syncope, or nocturnal agonal respiration
[7].
The Brugada syndrome becomes unmasked in associ-
ation with tricyclic antidepressant use, vagotonic agents,
cocaine, and alcohol intoxication and in a febrile state
[8, 9]. This is the reason why all the Brugada syndrome
patients need to be educated about the aggressive treatment
of fever and the medications to be avoided. ICD placement
is the main stay of treatment as pharmacologic treatment
has no mortality beneﬁt. DEBUT study has shown that
ICD treatment is superior to beta blockers [10]. New
pharmacological agents are still under experimental studies.
Symptomatic patients displaying the type 1 Brugada EKG
(either spontaneously or after sodium channel blockade),
who present with aborted sudden death, should receive an
ICD without additional need for electrophysiologic study
(EPS).
Asymptomatic patients can be divided into 2 main
categories: (1) those with a spontaneously occurring type 1
Brugada pattern and (2) those showing a type 1 Brugada
pattern after a drug challenge. Role of EPS inducibilityCase Reports in Medicine 3
amongasymptomaticpatientsiscontroversial.Inspiteofone
third of asymptomatic patients having inducible ventricular
arrhythmia, it does not seem to be equal to risk [11]. In
the past, asymptomatic Brugada syndrome patients were
associated with poor prognosis. Recent FINGER Brugada
syndrome registry showed that in asymptomatic individuals
the cardiac event rate per year was only 0.5%. Symptoms
and spontaneous Type 1 Brugada syndrome are the strong
predictors of future arrhythmic events. Gender, familial
history of SCD, presence of an SCN5A mutation, and
inducibility of ventricular arrhythmia were not predictive of
arrhythmic events [12].
4. Conclusions
Physicians, especially emergency department and general
physicians, should be aware of Brugada EKG patterns in
the diﬀerential diagnosis of ST-segment elevation in anterior
precordial leads of EKG. In a majority of the cases, and
especially in young patients, consultation with a cardiologist
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